AIkido Pharma Inc. (AIKI) |
|
3.56 0.03 (0.85%)
|
12-22 00:00 |
|
Open: |
3.55 |
Pre. Close: |
3.53 |
|
High:
|
3.66 |
Low:
|
3.5 |
|
Volume:
|
31,931 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-03-03 4:47:20 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.95 One year: 5.78 |
| Support: |
Support1: 3.81 Support2: 3.54 |
| Resistance: |
Resistance1: 4.23 Resistance2: 4.95 |
| Pivot: |
3.91 |
| Moving Average: |
MA(5): 3.92  MA(20): 3.91
MA(100): 4.56 MA(250): 3.92 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 30.9 %D(3): 42.5 |
| RSI: |
RSI(14): 51.5 |
| 52-week: |
High: 7.26 Low: 0.28 |
| Average Vol(K): |
3-Month: 36 (K) 10-Days: 41 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIKI ] has closed above bottom band by 47.4%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.92 - 3.95 |
3.95 - 3.97 |
|
Low:
|
3.7 - 3.72 |
3.72 - 3.75 |
|
Close:
|
3.86 - 3.9 |
3.9 - 3.94 |
|
Company Description |
|
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York. |
Headline News |
Wed, 01 Mar 2023
Dominari Holdings Provides Update on Share Repurchase Program - Marketscreener.com
Thu, 22 Dec 2022
AIkido Pharma Announces Name and Stocker Ticker Symbol ... - PR Newswire
Mon, 17 Oct 2022
The 1001 Imploded Stocks of 2022 (Down 80% or More)… So Far - WOLF STREET
Tue, 09 Aug 2022
Investor Makes Proposal to Acquire AIkido Pharma for $8.00 Per ... - GlobeNewswire
Thu, 21 Jul 2022
AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial ... - PR Newswire
Thu, 24 Mar 2022
Where Does Wall Street Think Aikido Pharma Inc (AIKI) Stock Will Go? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
13.2 (%) |
|
% Held by Institutions
|
10.8 (%) |
|
Shares Short
|
70 (K) |
|
Shares Short P.Month
|
75 (K) |
Stock Financials |
|
EPS
|
-1.85 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
15.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-9.2 |
|
Return on Equity (ttm)
|
-18.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-11 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-2.11 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.24 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.99 |
Stock Dividends |
|
Dividend
|
1 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
25.6% |
|
Dividend Pay Date
|
2019-05-09 |
|
Ex-Dividend Date
|
1980-05-11 |
|
Your Ad Here
|
|
